Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Gut

Volumn 43, Issue 4, 1998, Pages 445-449

  Todryk, S M ^a   Chong, H ^a   Vile, R G ^a   Pandha, H ^a   Lemoine, N R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; IMMUNOMODULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; SUICIDE GENE; TUMOR IMMUNITY; VACCINATION;

EID: 0031710994     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.4.445     Document Type: Article

References (90)

1. Beart RW. Colon and rectum. In: Abeloff MD, ed. Clinical oncology, Edinburgh: Churchill Livingstone, 1995:1267-86.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
3. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
4. Smith ME, Marsh SG, Bodmer JG, et al. Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci USA 1989;86:5557-61.
5. Browning M, Petronzelli F, Bicknell D, et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996;47:364-71.
6. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 1994;145: 505-9.
7. Fossum B, Gedde DT, Breivik J, et al. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int J Cancer 1994;56:40-5.
8. Qin H, Chen W, Takahashi M, et al. A CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 1995;55:2984-7.
9. Kim JA, Martin E Jr, Morgan CJ, et al. Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal cancer. Cancer Biother 1995;10:115-23.
10. Ransom JH, Pelle BA, Hubers H, et al. Identification of colon-tumor-associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumor-cell bacillus Calmette-Guerin vaccine. Int J Cancer 1993;54:734-40.
11. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 1995;82:13-17.
12. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-82.
13. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89.
14. van-de-Wiel-van-Kemenade H, Ligtenberg MJ, de-Boer AJ, et al. Episialin (MUCI) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993;151:767-76.
15. Barnd DL, Lan, MS, Metzgar RS, et al. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:159-63.
16. Gimmi CD, Morrison BW, Mainprice BA, et al. Breast cancer-associated antigen, DF3/MUCI, induces apoptosis of activated human T cells. Nat Med 1996;2:1367-70.
17. Svennevig JL, Lunde OC, Holter J, et al. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984;49:375-7.
18. Di Giorgio A, Botti C, Tocchi A, et al. The influence of tumor lymphocytic infilration on long term survival of surgically treated colorectal cancer patients. Int Surg 1992;77:256-60.
19. Takii Y, Hashimoto S, Iiai T, et al. Increase in the proportion of granulated CD56+ T cells in patients with malignancy. Clin Exp Immunol 1994;97:522-7.
20. Jackson PA, Green MA, Marks CG, et al. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut 1996;38:85-9.
21. Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125:200-5.
22. Ostenstad B, Sioud M, Lea T, et al. Limited heterogeneity in the T-cell receptor V-gene usage in lymphocytes infiltrating human colorectal tumours. Br J Cancer 1994;69:1078-82.
23. Sensi M, Parmiani G. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol Today 1995;16: 588-95.
24. Ostenstad B, Lea T, Schlichting E, et al. Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area. Gut 1994;35:382-7.
25. Watanabe N, Hizuta A, Tanaka N, et al. Localization of T cell receptor (TCR)-gamma delta + T cells into human colorectal cancer: flow cytometric analysis of TCR-gamma delta expression in tumour-infiltrating lymphocytes. Clin Exp Immunol 1995;102:167-73.
26. Maeurer MJ, Martin D, Walter W, et al. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996;183:1681-96.
27. Rajasekar R, Sim GK, Augustin A. Self heat shock and gamma delta T-cell reactivity. Proc Natl Acad Sci USA 1990;87:1767-71.
28. Multhoff G, Botzler C, Jennen L, et al. Heat shock protein 72 on tumour cells: a recognition structure for natural killer cells. J Immunol 1997;158:4341-50.
29. Lazaris AC, Theodoropoulos GE, Davaris PS, et al. Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer. Dis Colon Rectum 1995;38:739-45.
30. Wei Y, Zhao X, Kariya Y, et al. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of gamma delta T cells and heat shock protein 70. Cancer Res 1996;56:1104-10.
31. Melcher A, Todryk S, Hardwick M, et al. Tumour immunogenicity is determined by the mechanism of cell death via induction of heat shock protein. Nat Med 1998;4:581-7.
32. Avery A, Paraskeva C, Hall P, et al. TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 1993;68:137-9.
33. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375-82.
34. Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993;55:96-101.
35. Burg C, Patry Y, Le-Pendu J, et al. Leukaemia inhibitory factor derived from rat colon carcinoma cells increases host susceptibility to tumour growth. Cytokine 1995;7:784-92.
36. Kubota Y, Sunouchi K, Ono M, et al. Local immunity and metastasis of colorectal carcinoma. Dis Colon Rectum 1992;35:645-50.
37. Harada M, Matsunaga K, Oguchi Y, et al. The involvement of transforming growth factor beta in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). Cancer Res 1995;55:6146-51.
38. Maeurer MJ, Walter W, Martin D, et al. Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol 1997;45:182-92.
39. Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of energy in T-cell clones. Nature 1992;356:607-9.
40. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610-12.
41. Matsuda M, Petersson M, Lenkei R, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995;61:765-72.
42. Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therpay. Immunol Today 1996;17:39-45.
43. O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
44. Moller P, Koretz K, Leithauser F, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994;57:371-7.
45. Shimizu Y, Iwatsuki S, Herberman RB, et al. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. Cancer Immunol Immunother 1991;32:280-8.
46. Yoo YK, Heo DS, Hata K, et al. Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2 [see comments]. Gastroenterology 1990;98:259-68.
47. Horn SS, Rosenberg SA, Topalian SL. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol Immunother 1993;36:1-8.
48. Bateman WJ, Donnellan I, Fraser IA, et al. Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma. Cancer Immunol Immunother 1995;41:61-7.
49. Jacob L, Somasundaram R, Smith W, et al. Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumour cells. Int J Cancer 1997;71:325-32.
50. Vile R, Russell SJ. Gene transfer technologies for the gene therapy of cancer. Gene Ther 1994;1:88-98.
51. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994;5:153-64.
52. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
53. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad USA 1993;90:3539-43.
54. Gunji Y, Tagawa M, Matsubara H, et al. Antitumor effect induced by the expression of granulocyte macrophage-colony stimulating factor gene in murine colon carcinoma cells. Cancer Lett 1996;101:257-61.
55. Chong H, Todryk S, Hutchinson G, et al. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local anti-tumour response and may generate systemic protective immunity. Gene Ther 1998;5:223-32.
56. Martinoffi A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995;25:137-46.
57. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996;56: 2531-4.
58. Rodolfo M, Zilocchi C, Melani C, et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 1996;157:5536-42.
59. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
60. Habicht A, Lindauer M, Galmbacher P, et al. Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro. Eur J Cancer 1995;2:396-402.
61. Lindauer M, Schackert HK, Gebert J, et al. Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells. J Mol Med 1996;74:43-9.
62. De Wit D, Flemming CL, Harris JD, et al. K. IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL). Clin Exp Immunol 1996;105:353-9.
63. Vile RG, Nelson JA, Castleden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994;54:6228-34.
64. Tanaka T, Kanai H, Okabe S, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 1996;56:1341-5.
65. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-93.
66. Hwu P, Yannelli J, Kriegler M, et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol 1993;150:4104-15.
67. Vile RG, Castleden J, Marshall R, et al Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997;71:267-74.
68. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996;93:11302-6.
69. Chen SH, Kosai K, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996;56:3758-62.
70. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene admixed with conventional adjuvants. Cancer Res 1994;54: 6022-6.
71. Trinh QT, Austin EA, Alurray DM, et al. Enzyme prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase ganciclovir enzyme prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995;55:4808-12.
72. Ohwada A, Hirschowitz EA, Crystal RG. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 1996;7:1567-76.
73. Corr M, Lee D, Carson D, et al. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996;184:1555-60.
74. Fossum B, Olsen AC, Thorsby E, et al. CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-ras-derived peptide (Gly13-Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 1995;40:165-72.
75. Fossum B, Gedde-Dahl T, Hansen T, et al. Overlapping epitopes encompassing a point mutation (12 Gly-Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur J Immunol 1993;23:2687-91.
76. Yanuck M, Carbone DP, Pendleton CD, et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993;53:3257-61.
77. Kantor J, Irvine K, Abrams S, et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia vaccine. J Natl Cancer Inst 1992;84:1084-91.
78. Conry RM, LoBuglio AF, Loechel F, et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumour activity. Gene Ther 1995;2:59-65.
79. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
80. Acres RB, Hareuveni M, Balloul JM, et al. Vaccinia virus MUC1 immunization of mice: immune responses and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunother 1993;14:136-43.
81. Graham R, Burchell J. Intramuscular immunization with MUC-1 cDNA can protect C57 mice challenged with MUC-1-expressing syngeneic tumor cells. Int J Cancer 1996;65:664-70.
82. Mori M, Inoue H, Mimori K, et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996;224:183-8.
83. Townsend A, Ohlen C, Rogers M, et al. Source of unique antigens. Nature 1994;371:662.
84. Henderson RA, Nimgaonkar MT, Watkins SC, et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996;56:3763-70.
85. Reeves M, Royal R, Lam J, et al. Retroviral transduction of human dendritic-cells with a tumor-associated antigen gene. Cancer Res 1990;56:5672-7.
86. Levitsky HI, Lazenby A, Hayashi RJ, et al. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994;179:1215-24.
87. Hoover H Jr, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11:390-9.
88. Rubin J, Galanis E, Pitot HC, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997;4:419-25.
89. Li W, Berencsi K, Basak S, et al. Human colorectal cancer (CRC) antigen CO17-1AGA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J Immunol 1997;159:763-9.
90. Diaz RM, Todryk S, Chong H, et al. Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Ther 1998;5:869-79.